Table 1.
The current COVID-19 nucleic acid vaccines and details.
| Vaccine Name | Technology | Developer/Company | Immunization Protocol | Immunity | Effectiveness | Current Status |
|---|---|---|---|---|---|---|
| ZyCoV-D | DNA vaccine |
Zydus Cadila (Ahmedabad, India) | 3 doses (2.0 mg/dose), 4 weeks apart | humoral and cellular immunity | 66.6% | approved by India |
| INO-4800 | DNA vaccine |
Inovio (Plymouth Meeting, PA, USA) |
2 doses (2.0 mg/dose), 4 weeks apart | humoral and cellular immunity | unpublished results | phase Ⅱ/Ⅲ clinical trials |
| AG0302-COVID19 | DNA vaccine |
AnGes (Osaka, Japan) | 2 doses (2.0 mg/dose), 2/4 weeks apart | unpublished results | unpublished results | phase Ⅱ/Ⅲ clinical trials |
| GX-19N | DNA vaccine |
Genexine (Seoul, Korea) | unpublished results | unpublished results | unpublished results | phase Ⅱ/Ⅲ clinical trials |
| BNT162b2 | mRNA vaccine |
Pfizer (New York, NY, USA)/BioNTech (Mainz, Germany) | 2 doses (30 μg/0.3 mL/dose), 3 weeks apart | humoral and cellular immunity | 95.0% | approved by WHO |
| mRNA-1273 | mRNA vaccine |
Moderna (Cambridge, MA, USA) | 2 doses (100 μg/0.5 mL/dose), 28 days apart | humoral and cellular immunity | 94.1% | approved by WHO |
| ARCoV | mRNA vaccine |
WALVAX (Yunnan, China)/ABOGEN (Suzhou, China) | unpublished results | humoral and cellular immunity | unpublished results | phase Ⅱ/Ⅲ clinical trials |